TheEdgeResearch
Home / Stocks / FWPAY

Forward Pharma A/S (FWPAY)

OTC Healthcare Biotechnology
$300.00 ▼ -25.09%
Market Cap
$7.4M
Sector
Healthcare
Industry
Biotechnology
Beta
1.02
52-Wk Range
200.0-882.85626
CEO
Claus Bo Søndergaard Svendsen
Country
DK
Currency
USD

Forward Pharma A/S operates in the Biotechnology industry of the Healthcare sector, headquartered in Copenhagen, DK. The stock last traded at $300.00, down 25.09% on the session, giving a market capitalisation of $7.4M. On trailing twelve-month figures it carries a trailing P/E of -3.88, a net margin of 0.0%. Its beta of 1.02 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-3.88
Price / Sales
0.00
Price / Book
0.10
EV / EBITDA
33.47
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
117.44
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
4
IPO date
2014-10-15
Headquarters
Copenhagen, DK
About Forward Pharma A/S

Forward Pharma A/S presently engages in very limited business activities. In the past, this biopharmaceutical firm concentrated its efforts on developing FP187, its distinctive formulation of dimethyl fumarate, which was aimed at addressing both inflammatory and neurological conditions. The company was founded in 2005 and its headquarters are located in Copenhagen, Denmark.

Comparable companies

Forward Pharma A/S is most often compared with the following Healthcare names:

BNOEFCRBKFFLWPFHBCNFIMUNIPCIFPOLXFPSCBFTBPMFTRYPF
More research on FWPAY
FWPAY technical analysis FWPAY TheEdge Score Compare against peers
Open full interactive analysis & DCF →